New cohort shows the impact of hepatitis B and hepatitis C on the 'baby boom' generation

Michael Carter
Published: 11 November 2012

A new US study provides more evidence of the disproportionate impact of viral hepatitis infections on the 'baby boom' generation. Writing in the online edition of Clinical Infectious Diseases, investigators from the newly established Chronic Hepatitis Cohort Study (CHeCS) reported that 75% of hepatitis C infections were among patients born between 1945 and 1964, with half of all hepatitis B infections located in the same age group.

Both infections had a significant health impact, with high rates of hospitalisation and death.

“The mortality rates and relative youth of CHeCS patients who were dying was…notable,” comment the authors.

An estimated 3.2 million individuals in the US have chronic hepatitis C infection and another 1 million have chronic hepatitis B infection.

Neither infection has been recognised as a serious threat to public health until recently. As a result, surveillance, prevention and treatment programmes have been inadequate and poorly resourced.

Doctors wished to “assess the larger implications and impact of chronic hepatitis B and C on the US population”. They therefore established the CHeHS cohort.

The cohort involves approximately 11,000 patients who received care for either hepatitis B or C between 206 and 2008 in the cities of Detroit (Michigan), Danville (Pennsylvania), Portland (Oregon) and Honolulu (Hawaii). It is “dynamic”, meaning that new patients will be added to the cohort as they enter care.

The present study reported on the baseline demographics, liver biopsy status, hospitalisation and mortality rates with follow-up to the end of 2010.

To be eligible for inclusion in the cohort, participants had to be aged over 18 and have confirmed chronic hepatitis B or chronic hepatitis C infection.

The hepatitis B-infected cohort comprised 2202 people. They had been receiving care for a median of 5.3 years and contributed a total of 14,034 person-years of follow-up.

Approximately half were born between 1945 and 1964, with an additional 23% born between 1965 and 1974.

Most (57%) were men, 58% were Asian or Pacific Islander and13% were black. Over three-quarters (76%) had private health insurance.

Just over a fifth (22%) had undergone liver biopsy. On average, 9% of the cohort were hospitalised each year. A total of 706 participants (47%) had an undetectable viral load, and 58% of these individuals had received antiviral treatment.

By the end of 2010, 9% of participants had died. Approximately half these deaths (57%) occurred in people aged between 44 and 63 years.

The hepatitis C-infected cohort comprised 8810 participants. They had been receiving care for a median of 5.3 years.

Three-quarters of participants belong to the 'baby boom' generation and were born between 1945 and 1964. Most (60%) were men, 70% were white and 23% were black. Just under two-thirds (62%) of participants had private health insurance.

Viral load results were available for 63% of patients, and the most recent values were undetectable for a fifth of these individuals. The majority of those (80%) with an undetectable viral load had received antiviral treatment. Overall, 38% of patients had received hepatitis C therapy.

Between 2001 and 2010, 38% of hepatitis C-infected patients had a liver biopsy and 28% were tested for HIV. There was a 3% prevalence of HIV co-infection.

Approximately 13% of participants were hospitalised each year. Fourteen per cent of participants had died by the end of 2010, a mortality rate of 33 per 1000 person-years. There was an especially high mortality rate among those born during the 'baby boom' years, a quarter of whom died.

“Data from CHeCS are already yielding unique and useful information that may be used for public health action and policy development,” comment the investigators. “Our results strongly support the new policy of ‘birth cohort’ testing of those born in 1945 through 1964. This approach is likely to be more effective than the previous risk-based testing strategy in identifying persons infected with HCV in the distant past.”

They expect the cohort will “yield much data-driven information about the impact of therapies, comorbidities, and conditions on the general population with HBV and HCV in the future”.


Moorman AC et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. Clin Infect Dis, online edition. DOI: 10.1093/cid/cis815, 2012.

Tell us why you visited aidsmap today

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?


Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email

Hepatitis information

For more information on hepatitis visit

Infohep is a project we're working on with the World Hepatitis Alliance and the European Liver Patients Association.

Visit >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.